UA35583C2 - Застосування антигенного та/або імунорегулюючого матеріалу, одержаного з mycobacterium vaccаe, для лікування психічного захворювання, зв`язаного з аутоімунною реакцією, викликаною інфекцією - Google Patents

Застосування антигенного та/або імунорегулюючого матеріалу, одержаного з mycobacterium vaccаe, для лікування психічного захворювання, зв`язаного з аутоімунною реакцією, викликаною інфекцією

Info

Publication number
UA35583C2
UA35583C2 UA94095856A UA94095856A UA35583C2 UA 35583 C2 UA35583 C2 UA 35583C2 UA 94095856 A UA94095856 A UA 94095856A UA 94095856 A UA94095856 A UA 94095856A UA 35583 C2 UA35583 C2 UA 35583C2
Authority
UA
Ukraine
Prior art keywords
antigenic
infection
autoimmune response
material isolated
disorders due
Prior art date
Application number
UA94095856A
Other languages
English (en)
Russian (ru)
Inventor
Джон Лоосон Стенфорд
Грехем Артур Уільям Руук
Грехем Артур Вильям Руук
Original Assignee
Стенфорд Рук Лімітед
Стенфорд Рук Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стенфорд Рук Лімітед, Стенфорд Рук Лимитед filed Critical Стенфорд Рук Лімітед
Publication of UA35583C2 publication Critical patent/UA35583C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Soil Working Implements (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
  • Saccharide Compounds (AREA)

Abstract

Винахід належить до лікування психічних захворювань, супроводжуваних аутоімунними реакціями інфекційного походження, а також до наслідків хронічних інфекцій, пов'язаних з аутоімунітетом (окрім увеїту). Пропонується застосування антигенного та/або імунорегуляторного матеріалу, одержаного з Mycobacterium vассае, для лікування психічного захворювання, пов'язаного з аутоімунною реакцією, викликаною інфекцією.
UA94095856A 1992-02-21 1993-02-19 Застосування антигенного та/або імунорегулюючого матеріалу, одержаного з mycobacterium vaccаe, для лікування психічного захворювання, зв`язаного з аутоімунною реакцією, викликаною інфекцією UA35583C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929203814A GB9203814D0 (en) 1992-02-21 1992-02-21 Treatment of long term auto-immune conditions
PCT/GB1993/000351 WO1993016727A1 (en) 1992-02-21 1993-02-19 Mycobacterium vaccae for treatment of long term autoimmune conditions

Publications (1)

Publication Number Publication Date
UA35583C2 true UA35583C2 (uk) 2001-04-16

Family

ID=10710862

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94095856A UA35583C2 (uk) 1992-02-21 1993-02-19 Застосування антигенного та/або імунорегулюючого матеріалу, одержаного з mycobacterium vaccаe, для лікування психічного захворювання, зв`язаного з аутоімунною реакцією, викликаною інфекцією

Country Status (24)

Country Link
US (1) US5885588A (uk)
EP (2) EP0763361B1 (uk)
JP (1) JPH07506093A (uk)
KR (1) KR100275862B1 (uk)
AT (2) ATE192046T1 (uk)
AU (2) AU675421B2 (uk)
BG (1) BG99054A (uk)
BR (1) BR9305946A (uk)
CA (1) CA2130117A1 (uk)
CZ (1) CZ282651B6 (uk)
DE (2) DE69328503T2 (uk)
DK (2) DK0763361T3 (uk)
ES (2) ES2145968T3 (uk)
FI (1) FI943849A0 (uk)
GB (1) GB9203814D0 (uk)
GR (2) GR3024113T3 (uk)
HU (1) HU218347B (uk)
NO (1) NO311169B1 (uk)
NZ (1) NZ249518A (uk)
RO (1) RO117833B1 (uk)
RU (1) RU2124367C1 (uk)
SK (1) SK99994A3 (uk)
UA (1) UA35583C2 (uk)
WO (1) WO1993016727A1 (uk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
IL110011A (en) * 1994-06-13 2004-09-27 Yeda Res & Dev Pharmacological preparations for the treatment of schizophrenia
GB9505658D0 (en) * 1995-03-21 1995-05-10 Univ London Hormone and growth factor mimetics
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
AU741016B2 (en) * 1996-08-29 2001-11-22 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
RU2197989C2 (ru) * 1996-12-18 2003-02-10 Стэнфорд Рук Лимитед ПРИМЕНЕНИЕ Mycobacterium vaccae ДЛЯ РЕГУЛЯЦИИ ПО ТИПУ ОТРИЦАТЕЛЬНОЙ ОБРАТНОЙ СВЯЗИ Th2-АКТИВНОСТИ ИММУННОЙ СИСТЕМЫ
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
RU2137137C1 (ru) * 1997-12-03 1999-09-10 Научно-исследовательский институт по изучению лепры Способ определения m.leprae у больных с регрессом заболевания
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
NZ505834A (en) * 1997-12-23 2002-12-20 Genesis Res & Dev Corp Ltd Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
JP2003510335A (ja) * 1999-08-06 2003-03-18 コリクサ コーポレイション 自己免疫疾患の処置のためのワクチン
GB0010496D0 (en) * 2000-04-28 2000-06-14 Stanford Rook Ltd Treatment of conditions of the central nervous system
GB0106985D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeutic agent
GB0106986D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeutic agent
WO2005049056A2 (en) * 2003-11-14 2005-06-02 Ucl Biomedica Plc Immune modulator comprising whole cell rhodococcus, gordonia, nocardia, dietzia, tsukamurella or nocardioides bacteria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens

Also Published As

Publication number Publication date
US5885588A (en) 1999-03-23
SK99994A3 (en) 1995-05-10
GR3033772T3 (en) 2000-10-31
FI943849A0 (fi) 1994-08-22
GB9203814D0 (en) 1992-04-08
JPH07506093A (ja) 1995-07-06
EP0630259B1 (en) 1997-04-16
EP0763361A2 (en) 1997-03-19
ES2145968T3 (es) 2000-07-16
AU706122B2 (en) 1999-06-10
RO117833B1 (ro) 2002-08-30
WO1993016727A1 (en) 1993-09-02
ATE192046T1 (de) 2000-05-15
NZ249518A (en) 1997-07-27
NO943082D0 (no) 1994-08-22
ATE151641T1 (de) 1997-05-15
NO943082L (no) 1994-10-17
AU7188796A (en) 1997-02-06
HU218347B (hu) 2000-08-28
EP0630259A1 (en) 1994-12-28
DK0763361T3 (da) 2000-08-07
KR100275862B1 (ko) 2000-12-15
HU9402422D0 (en) 1994-10-28
DE69328503D1 (de) 2000-05-31
BR9305946A (pt) 1997-10-21
DE69309915T2 (de) 1997-07-24
AU3637793A (en) 1993-09-13
DE69328503T2 (de) 2000-08-24
NO311169B1 (no) 2001-10-22
EP0763361A3 (en) 1997-03-26
DK0630259T3 (da) 1997-09-15
CZ282651B6 (cs) 1997-08-13
HUT69941A (en) 1995-09-28
EP0763361B1 (en) 2000-04-26
CA2130117A1 (en) 1993-09-02
CZ202394A3 (en) 1995-02-15
ES2104131T3 (es) 1997-10-01
RU94045825A (ru) 1997-02-20
DE69309915D1 (de) 1997-05-22
GR3024113T3 (en) 1997-10-31
BG99054A (en) 1995-08-28
RU2124367C1 (ru) 1999-01-10
AU675421B2 (en) 1997-02-06
KR950700755A (ko) 1995-02-20

Similar Documents

Publication Publication Date Title
EP1003773A4 (en) EPTOPES OF CYTOTOXIC T CELLS FROM EPSTEIN BARR VIRUS
MY131388A (en) Inhibitors of hiv protease useful for the treatment of aids.
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
GB9024320D0 (en) Treatment of uveitis
IL97909A (en) Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences
ES2104131T3 (es) Mycobacterium vaccae utilizado en el tratamiento de afecciones auto-inmunes de larga duracion.
NZ212461A (en) Thymopoietin and spleenin like peptides
DE3485873D1 (en) Herpes simplex virus subunitimpfstoff.
AP9600861A0 (en) Immunotherapeutic agent and its use.
RU93004600A (ru) Применение mycobacterium vaccae, способ лечения, продукт m vaccae, иммунотерапевтический агент
ES2125331T3 (es) Agente terapeutico obtenido a partir de micobacterium vaccae y su utilizacion para luchar contra la infeccion vih con sida.
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
CA2064029A1 (en) Use of mycobacterium vaccae in the prevention of aids
MY111543A (en) Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
PT600396E (pt) Vacinas contra protozoarios intestinais
FR2374911A1 (fr) Adjuvants d'immunite non specifique
MY106961A (en) Antiviral tetrahydroimidazo[1,4] benzodiazepines
EP1143981A4 (en) TREATMENT AND PREVENTION OF HIV AND OTHER VIRUS INFECTIONS
EP0861077A4 (en) HEMOREGULATORY COMPOUNDS
RU93005016A (ru) Иммунорегуляторные и нейрорегуляторные пентапептиды, фармацевтические композиции на их основе, способ получения пентапептидов, способ лечения
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus